A new CDC study finds Moderna’s and Pfizer’s COVID-19 vaccines reduce the risk of infection by 91% for fully vaccinated individuals. For the few individuals who do get COVID, vaccination makes illness milder, shorter, AND appear to be less likely to spread the virus to others!
Importantly, this study is among the first to show that vaccination benefits individuals who get COVID-19 despite being fully vaccinated (14 or more days after their second dose) or partially vaccinated (14 or more days after first dose to 13 days after second dose).
3,975 participants completed weekly SARS-CoV-2 testing for 17 consecutive weeks (from December 13, 2020 to April 10, 2021) in eight U.S. locations. The findings come from four weeks of additional data collected in CDC’s HEROES-RECOVER study of health care workers, first
responders, frontline workers, and other essential workers (all high-risk, mind you). Once fully vaccinated, risk of infection was then reduced by 91% After partial vaccination, risk of infection was then reduced by 81%. This includes BOTH symptomatic and asymptomatic infection!
The study indicates that those who became infected after being fully or partially vaccinated were more likely to have a milder and shorter illness compared to those who were unvaccinated. For example, fully or partially vaccinated individuals who developed COVID-19 spent on
average SIX fewer total days sick and TWO fewer days sick in bed. They also had about a 60% lower risk of developing symptoms, like fever or chills, compared to those who were unvaccinated. Some study participants infected with SARS-CoV-2 did not develop symptoms.
The study also showed that fully or partially vaccinated individuals who got COVID-19 might be less likely to spread the virus to others. For example, fully or partially vaccinated study participants had 40% less detectable virus in their nose (lower viral load), and the virus
was detected for six fewer days (viral shedding) compared to those who were unvaccinated when infected. In addition, those who were partially or fully vaccinated were 66% LESS likely to test positive for SARS-CoV-2 infection for more than one week compared to those who were
unvaccinated. This information can be found here: cdc.gov/media/releases… and the start of study can be found here: cdc.gov/mmwr/volumes/7…
It is very important for everyone to know that these vaccines ARE indeed effective against current circulating variants of concern. Daily COVID-19 case rates, hospitalizations, and deaths continue to decline across the country but we have to keep going. If you have questions,
or concerns, it’s better to ask and get the right information. The resources are there. I’ll answer as much as I can as well. It’s important to vaccinate in order to control spread. In addition, if you need help finding a vaccine, please see: vaccines.gov/search/
Going to add this onto here. A recent study out of Nature shows us exactly how effective these vaccines indeed are against variants B.1.525, B.1.617.1, B.1.617.2 (Delta) AND B.1.618. Vaccinated sera successfully neutralized ALL variants. See: nature.com/articles/s4158… Image

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Mac n’ Chise 🧬🦠🧫

Mac n’ Chise 🧬🦠🧫 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

11 Jun
If you’re confused about the newest PHE data and want to know if the vaccines are effective against Delta (B.1.617.2) the answer is YES, indeed they are. Do you need both doses? YES, indeed you do. By the way, they’re effective against infection AND severe disease. Let’s discuss.
As of June 7th:
•Infections: 68% unvaccinated, 6% fully vaccinated
•Hospital Admissions: 65% unvaccinated, 11% fully vaccinated
•Deaths: 55% unvaccinated, 29% fully vaccinated (remember we need to consider age, health conditions, etc.) Image
Looking at PHE data, during the period of time that Delta became prevalent, there has been NO increase in PCR-positive participants in the SIREN (NHS healthcare workers) cohort overall AND reinfections remain at very LOW numbers. Image
Read 10 tweets
7 Jun
Some good news for your morning! A recent study out of India shows:
•Both Covishield (AstraZeneca) and Covaxin prompted good immune response after two doses
•95% of participants (N=515, HCWs) showed seropositivity (higher antibodies) after two doses of either vaccine
•A total of 27 breakthrough infections (4.9%) were recorded among respondents who had received both doses of either of the vaccines. Out of these, 25 were mild and two were moderate cases of breakthrough infections
•NO deaths were recorded as a result of breakthrough infections
•Seropositivity rates and median anti-spike antibody titre was significantly higher in Covishield (AstraZeneca) recipients
•Of the 425 Covishield (AstraZeneca) and 90 Covaxin recipients, 98.1% and 80% respectively, showed seropositivity
Read 8 tweets
4 Jun
I figured it was best to make a comprehensive thread concerning the study out of The Lancet concerning variant B.1.617.2 (Delta) after mRNA vaccination to help clear up some confusion. Most aren’t breaking it down into layman’s terms, so allow me. Let’s discuss.
Firstly, 250 people, one study, one assay. Median age was 42, fairly healthy. We have established the evasiveness of B.1.617.2 is similar to B.1.351. Got it? Okay, good. I’ll make this simple and put it into bullet points. Study can be found here: thelancet.com/journals/lance…
•One dose is not enough, two are needed for high levels of nAbs. Yes, we knew this. It also falls in line with PHE data from last week
•EXTREMELY IMPORTANT TO NOTE: Antibody neutralization is NOT the same as vaccine efficacy, as in a 5.8-fold reduction in antibody
Read 14 tweets
1 Jun
This is fantastic! Real-world data out of Butantan Institute São Paulo, Brazil shows after ~75% of Serrana’s population had been vaccinated with Coronavac:

•95% reduction in deaths
•86% reduction in hospitalizations
•90% reduction in IC
•80% reduction in symptomatic cases
Total vaccinated population: 27,150 (97.7% of adult population vaccinated with first dose; 95% vaccinated with second dose). Keep in mind, this is in the face of variants of concern including P.1. 75% of Serrana’s population had been vaccinated with Coronavac from February-April.
For comparison purposes, Serrana was compared with Jardinópolis, a nearby city. The death curves were similar UNTIL Serrana began vaccinating. After vaccination (first graphic), we can see deaths rose in Jardinópolis (blue) but dropped significantly in Serrana (orange).
Read 8 tweets
29 May
This is so encouraging! A recent study demonstrates detection and longitudinal persistence of SARS-CoV-2 IgG antibodies in the upper respiratory tract following COVID-19 vaccination. What does this mean? Prevention of SARS-CoV-2 infection AND transmission! Let’s discuss!
Researchers enrolled 114 individuals who had received their first dose of Moderna’s vaccine within 3-7 days and collected oral mucosal fluid samples on days 5, 10, 15, and 20 after each vaccine dose. Of those who were naive (no history of previous infection) to SARS-CoV-2
(n = 89), 79 (85.4%) tested positive for SARS-CoV-2 IgG antibodies by time point 2 (10 days +/-2 days after first vaccine dose), and 100% tested positive for SARS-CoV-2 IgG by time point 3 (15 days +/-2 days after first vaccine dose). And that’s with just one dose!
Read 13 tweets
26 May
Immunological memory for the win! Two new studies show immunity to Coronavirus lasts AT LEAST a year, possibly a lifetime, AND improves over time, ESPECIALLY when paired with vaccination!
The first study shows those who had been previously had an infection have cells that retain a memory of the virus persist in their bone marrow and produce antibodies whenever needed, demonstrating a SARS-CoV-2 infection induces a robust antigen-specific,
long-lived humoral immune response in humans. Find that study here: nytimes.com/2021/05/26/hea…. The second study is still being reviewed before publication in Nature but found memory B-cells continue to mature and strengthen for at least 12 months after initial infection!
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!